Welcome to In the Spotlight, where each month we shine a light on something exciting, timely, or simply fascinating from the world of science.
In recognition of Heart Health Month, we’re spotlighting the importance of cardiovascular wellness. From risk factors and prevention to innovative treatments, we’re exploring the science and stories shaping heart health today.
Latest News Releases
Updates every hour. Last Updated: 26-Apr-2026 03:16 ET (26-Apr-2026 07:16 GMT/UTC)
Genetic study finds new pathways involved in cardiometabolic disease
University of OklahomaPeer-Reviewed Publication
- Journal
- PLOS Medicine
- Funder
- National Institute of Diabetes and Digestive and Kidney Diseases
The beating of the heart suppresses growth in cardiac cancers
American Association for the Advancement of Science (AAAS)The heart’s constant beating may actively suppress tumor growth in cardiac tissues, a new study reports. This is because cellular pathways in these tissues alter gene regulation in cancer cells to keep them from proliferating. The findings shed light on the role of mechanical forces in protecting the heart from cancer and may pave the way to new cancer therapies based on mechanical stimulation. Heart cancer is very rare in mammals. What’s more, the adult human heart has a limited capacity for self-renewal, with cardiomyocytes regenerating at roughly 1% per year. One proposed explanation for these features lies in the intense mechanical demands placed on heart tissues, which must continuously pump blood against significant resistance. Such persistent strain appears to suppress the ability of heart cells to proliferate. According to Giulio Ciucci and colleagues, these pressures may also inhibit the proliferation of cancer cells in the heart. However, the mechanisms underlying this resistance remain unclear.
Using a genetically engineered mouse model, Ciucci et al. found that the heart is remarkably resistant to cancer-causing mutations, even when potent oncogenic changes were introduced. To understand why, the authors developed a transplantation model in which the heart’s mechanical workload could be reduced. By grafting a donor heart into the neck of a compatible mouse, they created a “mechanically unloaded” organ, one that remained perfused with blood but did not bear physiological strain. After injecting human cancer cells directly into the heart muscle, they compared tumor behavior in the unloaded transplanted heart versus the animal’s native, mechanically active heart. Across their experiments, Ciucci et al. found that mechanical load consistently suppressed the growth of various cancer types, while unloading the heart promoted tumor cell proliferation within cardiac tissue. According to the findings, mechanical forces within the tissue reshape the cancer cell genome’s regulatory landscape, influencing whether cells can proliferate. Central to this process is Nesprin-2, a protein that transmits mechanical signals from the cell surface to the nucleus. Nesprin-2, a component of the LINC complex, senses the mechanical microenvironment of the heart and functionally alters chromatin structure and histone methylation, reducing gene activity linked to tumor cell proliferation. When Nesprin-2 was silenced in cancer cells, those cells regained the ability to grow in the mechanically active environment of the heart, forming tumors. In a related Perspective, Wyatt Paltzer and James Martin discuss the study and its findings in greater detail.
For reporters interested in topics of research integrity, study co-author Serena Zacchigna notes: “We are working to ensure reproducibility of complex mechanobiology experiments, standardizing mechanical stimulation protocols, and validating results across models and labs. I also believe that data reporting is essential, as is rigorous assessment of safety and efficacy. Ethically, as a medical doctor, I believe that early patient involvement in the design of wearable technologies is a priority, avoiding overstated claims.”
Podcast: A segment of Science's weekly podcast with Giulio Ciucci, related to this research, will be available on the Science.org podcast landing page [http://www.science.org/podcasts] after the embargo lifts. Reporters are free to make use of the segments for broadcast purposes and/or quote from them – with appropriate attribution (i.e., cite "Science podcast"). Please note that the file itself should not be posted to any other Web site.
- Journal
- Science
Scientists find people with severe obesity and heart failure have weakened heart muscle contractions. Weight loss may reverse this condition
Johns Hopkins MedicinePeer-Reviewed Publication
- Journal
- Science
- Funder
- National Heart, Lung, and Blood Institute, National Institute of General Medical Sciences, American Heart Association, United States Department of Energy, National Science Foundation, Amgen, Steven M. Gootter Foundation
The beating of the heart suppresses growth in cardiac cancers
American Association for the Advancement of Science (AAAS)Peer-Reviewed Publication
The heart’s constant beating may actively suppress tumor growth in cardiac tissues, a new study reports. This is because cellular pathways in these tissues alter gene regulation in cancer cells to keep them from proliferating. The findings shed light on the role of mechanical forces in protecting the heart from cancer and may pave the way to new cancer therapies based on mechanical stimulation. Heart cancer is very rare in mammals. What’s more, the adult human heart has a limited capacity for self-renewal, with cardiomyocytes regenerating at roughly 1% per year. One proposed explanation for these features lies in the intense mechanical demands placed on heart tissues, which must continuously pump blood against significant resistance. Such persistent strain appears to suppress the ability of heart cells to proliferate. According to Giulio Ciucci and colleagues, these pressures may also inhibit the proliferation of cancer cells in the heart. However, the mechanisms underlying this resistance remain unclear.
Using a genetically engineered mouse model, Ciucci et al. found that the heart is remarkably resistant to cancer-causing mutations, even when potent oncogenic changes were introduced. To understand why, the authors developed a transplantation model in which the heart’s mechanical workload could be reduced. By grafting a donor heart into the neck of a compatible mouse, they created a “mechanically unloaded” organ, one that remained perfused with blood but did not bear physiological strain. After injecting human cancer cells directly into the heart muscle, they compared tumor behavior in the unloaded transplanted heart versus the animal’s native, mechanically active heart. Across their experiments, Ciucci et al. found that mechanical load consistently suppressed the growth of various cancer types, while unloading the heart promoted tumor cell proliferation within cardiac tissue. According to the findings, mechanical forces within the tissue reshape the cancer cell genome’s regulatory landscape, influencing whether cells can proliferate. Central to this process is Nesprin-2, a protein that transmits mechanical signals from the cell surface to the nucleus. Nesprin-2, a component of the LINC complex, senses the mechanical microenvironment of the heart and functionally alters chromatin structure and histone methylation, reducing gene activity linked to tumor cell proliferation. When Nesprin-2 was silenced in cancer cells, those cells regained the ability to grow in the mechanically active environment of the heart, forming tumors. In a related Perspective, Wyatt Paltzer and James Martin discuss the study and its findings in greater detail.
For reporters interested in topics of research integrity, study co-author Serena Zacchigna notes: “We are working to ensure reproducibility of complex mechanobiology experiments, standardizing mechanical stimulation protocols, and validating results across models and labs. I also believe that data reporting is essential, as is rigorous assessment of safety and efficacy. Ethically, as a medical doctor, I believe that early patient involvement in the design of wearable technologies is a priority, avoiding overstated claims.”
Podcast: A segment of Science's weekly podcast with Giulio Ciucci, related to this research, will be available on the Science.org podcast landing page after the embargo lifts. Reporters are free to make use of the segments for broadcast purposes and/or quote from them – with appropriate attribution (i.e., cite "Science podcast"). Please note that the file itself should not be posted to any other Web site.
- Journal
- Science
Worcester Polytechnic Institute researchers seek to uncover the path to heart valve failure
Worcester Polytechnic InstituteGrant and Award Announcement
Kristen Billiar, a professor in the Department of Biomedical Engineering, will try to determine what turns those risk factors into disease as part of a $15 million multi-center initiative that is funded by the American Heart Association [LE1] and focused on early detection and prevention of heart valve disorders.
- Funder
- American Heart Association
Rethinking newborn screening for critical congenital heart disease
Lehigh UniversityA Lehigh University bioengineering researcher is developing a new method to improve detection of critical congenital heart disease in newborns. Using seismocardiography—an approach that measures chest vibrations—the work aims to address key limitations of pulse oximetry, including reduced accuracy in some patients and missed conditions that do not affect blood oxygen levels.
New global consensus establishes blueprint for holistic cardiovascular implantable electronic device lead management and lifelong patient safety
ElsevierPeer-Reviewed Publication
- Journal
- Heart Rhythm
Genetic variations may hinder protective benefits of vitamin D on diabetes
Boston University School of MedicinePeer-Reviewed Publication
The Center for Disease Control estimates nearly 50% of the U.S. population has either prediabetes (38%) or type 2 diabetes (T2D). Vitamin D deficiency is common in individuals with T2D with a prevalence of more than 80%. Past studies have reported pre-diabetic adults on 4000 IUs vitamin D3/d (median of 2.5 years) received no benefit in reducing progression to type 2 diabetes (T2D) compared to placebo. While other studies have shown participants receiving vitamin D who maintained certain levels of serum 25-hydroxyvitamin D [25(OH)D], resulted in approximately 52% and 71% risk reductions.
In the latest issue of JAMA Network Open, Dawson-Hughes et al., examined four common vitamin D receptor (VDR) polymorphisms (common genetic variations in DNA sequences) and observed that subjects with the vitamin D receptor (VDR) ApaI AA alleles, received no benefit from vitamin D treatment. However, subjects with ApaI AC and CC genotypes showed a 19% decreased risk of progressing to T2D. Polymorphisms are associated with chronic disorders including autoimmune diseases, diabetes, heart disease, deadly cancers and Alzheimer's disease. Polymorphisms also disrupt drug responses by alterations in enzyme function, drug transport and receptors.
- Journal
- JAMA Network Open
GLP-1–based drug tirzepatide reduces heart risk in high-risk patients
Society for Cardiovascular Angiography and InterventionsMeeting Announcement